NCT06342609

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

Name: Clinical Trial NCT06342609
Creator: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Keywords: Coronary Artery Disease, Colchicine 0.5 MG, Phase 4, drug, clinical trial, United States of America

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With STable CoROnary Artery Disease CoMpared to Placebo - EKSTROM Trial

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·ClinicalTrials.gov·drugRecruitment Completed

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Coronary Artery Disease
Drug/Device/Intervention: Colchicine 0.5 MG
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Location: Torrance, United States of America

Timeline & enrollment

Phase: Phase 4
Start date: Mar 15, 2023
End date: Sep 07, 2024
Enrollment: 84 participants

Primary outcome

Rate of change in low attenuation plaque volume as measured by multidetector computed tomography (MDCT) angiography

Summary

This is a randomized double-blind, placebo-controlled, investigator-initiated trial that compares Colchicine 0.5mg/day with placebo, among patients with stable CAD. Subjects will be educated to maintain medication compliance with other prescribed medications.

ICD-10 classifications

Cardiovascular disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart diseaseAbnormal findings on diagnostic imaging of heart and coronary circulationCoronary vasodilators, not elsewhere classified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06342609
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06342609 through Pure Global AI's free database. This Phase 4 trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center and is currently Recruitment Completed. The study focuses on Coronary Artery Disease. Target enrollment is 84 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.